Adoptive T-cell therapy is clinically efficacious in the treatment of select cancers. However, it is often difficult to obtain adequate numbers of tumor-specific T cells for therapy. One method for overcoming this limitation is to generate tumor-specific T cells by retrovirally mediated T-cell-receptor (TCR) gene transfer. However, despite instances of therapeutic success, major obstacles remain, including attaining the survival of retrovirally modified T cells in vivo as well as inducing long-term and multi-gene retroviral expression. Using a murine model of adoptively transferred retrovirally modified CD8 þ T cells, where antitumor immunity was dependent on sustained, multigene expression, we found that in vitro assays are poor indicators of in vivo efficacy. Despite persisting for over 9 months in a nonlymphopenic environment, genetically modified T cells exhibited discordant retrovirally mediated gene expression in vivo not readily evident from initial in vitro assays. In particular, one of the two TCR subunit genes necessary for antigen specificity was selectively lost in vivo. As this discordant gene expression was associated with the loss of antitumor immunity, consideration of these findings may provide guidance in the design, evaluation and application of retroviral vectors for use in the treatment of cancer and other human disease.
Introduction
Adoptive T-cell therapy has shown efficacy in the treatment of select human cancers. 1 However, it is often difficult to isolate and expand tumor-specific T cells for subsequent adoptive transfer. One approach for overcoming this problem is to use retroviral vectors to artificially bestow tumor specificity to T cells by the transfer of tumor-specific T-cell-receptor (TCR) genes. [2] [3] [4] [5] Not only has this approach shown success in mouse models, 6, 7 but also efficacy was recently demonstrated in human cancer patients. 8 In the latter case, Morgan et al. demonstrated objective tumor responses in 2 of 15 patients adoptively transferred with TCR gene-modified T cells.
Despite these successes, significant limitations remain. One obstacle includes the difficulty in achieving the longterm survival of adoptively transferred T cells. The ability of adoptively transferred T cells to persist is important for the ability to clear tumor, 9 and in the study mentioned previously, Morgen et al. 8 showed that in the two responding patients, donor T cells persisted at high levels for at least 1 year after transfer. The complexity of this issue is often overlooked as the survival of adoptively transferred T cells is often measured in hosts that have undergone irradiation or other forms of cytoreduction depleting the host lymphocyte pool. In such cases of lymphodepletion, donor T cells engraft and survive much more efficiently. 10, 11 Were it possible to more efficiently engraft donor T cells in nonlymphopenic hosts, adoptive T-cell therapy might be more effective.
Another limitation in applying TCR gene transfer as a therapeutic is the inability to achieve reliable long-term and multigene expression in vivo. Successful TCR gene transfer to redirect T-cell specificity requires the sustained expression of two distinct TCR subunit genes (either the a and b TCR subunits, or in some cases the g and d TCR subunits), and in addition, the utility of retroviral vectors is often enhanced by the inclusion of a third gene mediating the selection of transduced cells. Although careful planning in the design of new retroviral vectors may reduce the likelihood of suboptimal gene expression, practical experience often tells us that the process is often unpredictable. 12 In the study by Morgen et al., 8 despite the persistence of donor T cells in two patients, retrovirally mediated TCR expression declined over time, likely limiting the therapeutic value.
As it is usually difficult to evaluate whether a given retroviral vector can direct gene expression in vivo, gene expression is often initially evaluated using in vitro assays. In particular, immortalized cell lines, which are easy to cultivate, are frequently selected as initial targets for retroviral transduction. Unlike primary cells that are in most situations the cellular targets for gene therapies, immortalized cell lines do not require the same degree of external stimuli to induce proliferation. The latter is necessary for retroviral transduction with the Moloney murine leukemia virus (MoMLV)-derived retroviral vectors. 13 These qualities make immortalized cell lines convenient vehicles to rapidly assess newly developed retroviral vectors for appropriate gene expression and function. For retroviral vectors that direct the expression of multiple genes, the use of an immortalized cell line can be particularly useful, as the evaluation of the vector may require more complex testing and the use of greater numbers of transduced cells. However, although the aforementioned differences that make them attractive in vitro targets for vector screening, it is not clear to what extent results obtained with retrovirally transduced immortalized cells lines are representative of those obtained with retrovirally transduced primary cells. Moreover, retrovirally modified cells may behave differently in vitro as compared with the complex in vivo environment.
For this study, we evaluated these issues using a previously characterized multigene retroviral vector designated ovASBN.
14 This retroviral vector encodes the genes to direct the expression of the ovalbumin-specific OT-I TCR (including the genes encoding for both the a and b OT-I TCR subunits) 15, 16 and the drug-resistant gene product to neomycin. The TCR a-subunit gene is driven off the MoMLV LTR promoter, whereas the TCR b-subunit gene is driven off the SRa promoter. The neomycin drug resistance gene is driven off an internal ribosome entry site (IRES) derived from the encephalomyocarditis virus. We have previously demonstrated T cells retrovirally modified with this ovASBN retroviral vector (designated B6 ovASBN-vector T cells) could functionally recognize relevant antigen in vitro with the same avidity as its parental T-cell clone. 14 Building on these previous results, our current focus was to evaluate the ability of B6 ovASBN-vector cells to function in a therapeutic manner in vivo. Contrary to our expectations based on in vitro results, we found no evidence that B6 ovASBN-vector cells could function therapeutically and mediate tumor regression in vivo. This was in contrast to the potent therapeutic effect of our positive control T cells and despite the ability of adoptively transferred B6 ovASBN-vector cells to persist in vivo. Detailed analysis of this problem revealed that there was discordant gene expression of the retrovirally encoded genes in vivo, when compared with what we observed in vitro. Specifically, we observed a loss in the expression of one of the retrovirally encoded genes in vivo and in certain in vitro situations. Interpretation of these results may provide guidance for the development and utilization of retroviral vectors in other circumstances.
Materials and methods

Animals
All mice used were 6-14 weeks old, purchased from the Jackson Laboratory (Bar Harbor, ME), and maintained in specific pathogen-free conditions at the Medical University of South Carolina (Charleston, SC) in accordance with the National Institutes of Health guidelines. C57BL/6-Ly5.1 (B6.SJL-Ptprc a
Pep3
b /BoyJ) mice are congenic to wild-type C57BL/6-Ly5.2 mice at the Ly5 (CD45) allele, 17 use of which allowed us to distinguish donor T cells following adoptive transfer. OT-I TCR transgenic mice express the OT-I TCR (Va2/ Vb5) transgene encoding a TCR specific for the OVA epitope (SIINFEKL-H2-K b ). 16 OT-I TCR transgenic/ Ly5.1 mice were generated by crossing OT-I mice to C57BL/6-Ly5.1 mice.
Antibodies and other reagents
The following monoclonal antibodies (mAbs) were used for this study: B20.1, anti-Va2; MR9-4, anti-Vb5; MR5-2, anti-Vb8.1/8.2; 145-2C11, anti-CD3e; 37.51, anti-CD28; A20, anti-Ly5.1 (CD45.1); 53-6.7, anti-CD8; IM7, anti-CD44; MEL-14, anti-CD62L; 53-6.7, anti-CD8; and 2.4G2, FC Block (all from BD Pharmingen, La Jolla, CA). Murine interleukin-2 (IL-2) was reconstituted in 0.1% bovine serum albumin (BSA)/phosphate-buffered saline and stored at À20 1C according to the manufacturer's recommendation (R&D Systems, Minneapolis, MN). The SIINFEKL peptide (OVA H-2K b ) epitope was synthesized by American Peptide (Sunnyvale, CA). Carboxyfluorescein diacetate, succinimidyl ester (CFSE) and carboxy SNARF-1, acetoxymethyl ester, acetate (SNARF) were purchased from Molecular Probes Inc. (Eugene, OR).
Flow cytometry
Cells were analyzed by flow cytometric analysis as previously described. 18 Briefly, cells were washed in fluorescence activated cell sorting (FACS) buffer consisting of 0.5% BSA and 0.02% sodium azide in Hanks' Balanced Salt Solution. Cells were prestained with Fc block for 5 min at 4 1C, incubated with mAb for 30 min at 4 1C and washed twice before analysis. Cell surface immunofluorescence was measured using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) and analyzed with FlowJo software (Ashland, OR) or CellQuest software (BD Biosciences).
Cell lines
All cell lines were maintained in complete RPMI-based medium as described previously.
14 B16-ova cells (B16 cells transfected with the ovalbumin gene) 19 were kindly provided by R Dutton (Trudeau Institute, NY) with the permission of E Lord (University of Rochester Medical Center, Rochester, NY) and maintained in complete medium supplemented with 500 mg ml À1 geneticin (also called G418 or neomycin; Invitrogen, Carlsbad, CA). The parental cell B16 line is a melanoma derived from C57BL/ 6-Ly5.2 mice. 20 58a À b À cells were kindly provided by E Palmer (Laboratory of Transplantation Immunology and Nephrology, University Hospital, Basel, Switzerland). 21 After retroviral transduction, 58a
À b À cells were selected in 800 mg ml À1 G418 and/or 400 mg ml À1 hygromycin B (Boehringer Mannheim, Indianapolis, IN).
Retroviral vector and supernatant production
Constructs containing OT-I TCR genes were kindly provided by Francis Carbone (University of Melbourne, Victoria, Australia). 15 As previously described, 14 the ovASBN retroviral vector was created by the insertion of the OT-TCR b gene into the XhoI restriction site and the insertion of the OT-I TCR a gene into the SalI restriction site of the 'pg1 SAMEN SRa' vector. For construction of the ovBSN and ovSBN constructs, the OT-I TCR b gene was inserted into the SalI or XhoI restriction enzyme sites, respectively. For construction of the ovASN and ovSAN constructs, the OT-I TCR a gene was inserted into the SalI or XhoI restriction enzyme sites, respectively. For construction of the ovAN and ovBN constructs, OT-I TCR a and b genes, respectively, were cloned into the XhoI restriction enzyme site of the previously described 'pgSAMEN' vector. 22 For the generation of constructs encoding the hygromycin B resistance gene, we modified the 'pgSAMEN' vector by the removal of the IRES-neomycin coding sequence (XhoI/BamHI fragment) and replacing this with IREShygromycin B coding sequence (BamHI/XbaI fragment from the 'pIREShyg' vector (Clontech, Mountain View, CA), resulting in the creation of the 'pgSAMEH' vector. The ovAH and ovBH retroviral constructs were then created by cloning the OT-I TCR a and b genes into the SalI restriction enzyme site of the 'pgSAMEH' vector, respectively. All retroviral vectors were transfected into GPE86 cells kindly provided by A Bank (Columbia University, New York, NY). 23 Packaging cell clones were isolated by limiting dilution and screened for those producing high-titer vector. Twenty-four hours before harvesting retroviral supernatant, the tissue culture medium was changed and retroviral supernatant was harvested, filtered (0.2 mm polyethersulfone) and frozen until use.
Transduction of murine T cells
Mouse T cells were retrovirally transduced as previously described 14 in a manner that selectively induces the proliferation of CD8 þ T cells. 24, 25 In brief, splenocytes were harvested from C57BL/6-Ly5.1 mice and activated with plate-bound anti-CD3e and anti-CD28 antibodies.
Forty-eight hours after stimulation, cultures were maintained by adding with murine IL-2 (20 ng ml
À1
) and viral supernatant every other day. On day 10 of culture, cells were restimulated with plate-bound ant-CD3e and anti-CD28 antibodies in the presence of G418 (500 mg ml
). On day 12, cultures were replated with IL-2 and G418. G418-resistant and live cells were expanded and used for experiments on days 15-17 of culture. In experiments where culture conditions were extended (as in Figure 6 ), cells were maintained at 1-2 million cells per milliliter and murine IL-2 (20 ng ml À1 ) was added every other day. Nomenclature for retrovirally modified T cells consisted of the mouse strain used for transduction plus the retroviral vector name in superscript (mouse strain name of vector ).
B16-ova tumor challenge
The B16-ova tumor challenge model used was a modification of a previously reported protocol.
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C57BL/6 mice were first injected intravenously (i.v.) with 500 000 B16-ova tumor cells. After 3 days, mice were treated by intravenous injection with 10 million retrovirally transduced T cells. Approximately 17 days after tumor challenge, mice were killed and lungs were harvested. Metastases were easily identified as discrete black spots on normal lung tissue and were counted in a blinded fashion.
In vivo cytotoxicity assay
The in vivo cytotoxicity model was a modification of a previously reported protocol. 27 Briefly, spleen cells were harvested from C57BL/6 mice and separated into two groups. One group was pulsed with SIINFEKL peptide (5 mg ml À1 ) for 2-3 h, whereas the other group was incubated in media alone. After the incubation, each group of cells was washed 3 Â and then labeled with a fluorescent dye. Target cells with peptide were labeled with 1.5 mM CFSE and target cells without peptide were labeled with 1.0 mM SNARF. In some experiments, target cells without peptide were labeled with 0.375 mM CFSE instead of 1.0 mM SNARF. Labeling was performed according to the directions from the manufacturer, Molecular Probes. As indicated, effecter T cells were also adoptively transferred into mice either before or after injection of target cells. Twelve hours after injection of target cells, spleens were harvested and analyzed by flow cytometry for target cells based on fluorescence with CFSE or SNARF.
Results
The functional ability of B6 ovASBN-vector cells in vivo We have previously demonstrated that T cells retrovirally modified with the ovASBN vector (B6 ovASBN-vector T cells) could recognize antigen in vitro with the same avidity as their parental T-cell clone. Therefore, we predicted that these B6 ovASBN-vector T cells would be efficacious at mediating antitumor immunity of tumors expressing relevant antigen. We tested this by injecting C57BL/6 mice intravenously with the well-characterized ovalbumin-expressing B16-ova tumor. 19 Three days after tumor injection, mice were treated by the adoptive transfer of 10 million retrovirally transduced B6 ovASBN-vector T cells. As controls, we adoptively transferred both negative and positive control T cells. Negative control T cells (designated B6
control-vector ) were generated by transducing C57BL/6T cells with a control retroviral vector, whereas positive control cells (designated OT-I control-vector ) were generated by transducing antigen-specific TCR transgenic OT-I T cells 16 with the same control vector. Three weeks after adoptive T-cell transfer, lungs were harvested and metastases were counted. As shown in One explanation for the lack of therapeutic effect of B6 ovASBN-vector cells in vivo might be a loss of antigenspecific avidity in vivo. In our previous report, we demonstrated that B6 ovASBN-vector cells have a high antigen-specific avidity in vitro similar to the positive control (OT-I control-vector ). However, it is possible that the relative avidity could be altered in vivo as compared with the in vitro environment. To address the question of antigen-specific avidity, we used peptide-pulsed cells as targets in vivo instead of tumor cells. The advantage of peptide-pulsed target cells is that they likely express a much higher level of antigen on their surface than tumor cells. Thus, if the B6 ovASBN-vector cells have a moderate reduction in antigen-specific avidity in vivo, we would expect them to likely retain the capacity to lyse peptidepulsed target cells. However, we found no evidence that B6 ovASBN-vector cells retained any ability to recognize antigen in vivo. Collectively, the results from these experiments show that unlike the ability of B6 ovASBN-vector cells to mediate antigen-specific functional ability in vitro, these B6 ovASBN-vector cells appeared to lack this functional capability in vivo. Furthermore, this functional deficiency in vivo was most likely not a result of a subtle loss in antigen-specific avidity.
B6
ovASBN-vector cells survive and disseminate in vivo A second potential explanation that could account for the discrepancy between the ability of the positive control OT-I control-vector cells and B6 ovASBN-vector cells to mediate antigen-specific functional ability might be a failure for the B6 ovASBN-vector cells to survive and disseminate in vivo. We addressed this by adoptively transferring retrovirally modified T cells into unirradiated Ly5 congenic B6 mice and assessing the distribution of the adoptively transferred cells in different organs over time. As shown in Figure 2 , retrovirally modified T cells were capable of surviving and disseminating to various organs throughout the mouse. Initially, during the first 5 days, the highest percentage of donor cells was found in the lung and the liver, consistent with where activated T cells would be expected to localize after intravenous tail vein injection. 28 Subsequently, the percentage of donor cells in the lung and the liver gradually decreased. In other sites, including the spleen, lymph node (LN), and peripheral blood (PBL), the percentage of donor cells peaked around days 7-14, after which there was a gradual decrease in the percentage . These results clearly demonstrate that the inability of the retrovirally modified T cells to function in vivo was not related to a failure to survive or disseminate to the appropriate locale.
B6 ovASBN-vector cells display discordant gene expression in vivo
Having demonstrated the capacity of B6 ovASBN-vector cells to localize appropriately in vivo, we next assessed whether these cells also maintained expression of the retrovirally encoded TCR a-and b-subunits in vivo, a prerequisite for the possession of functional activity. Because there are no clonotypic antibodies available against the OT-I TCR, we utilized antibodies against the shared Va2 and Vb5 regions used by the a-and b-subunits of the OT-I TCR. B6 ovASBN-vector cells showed a high but heterogeneous level of TCR Va2 expression in vivo (Figure 3, top panel) , similar to the pattern of expression observed in vitro. Figure 2) . Cumulatively, these data indicate that the differences we have observed with Va2 expression among the different T-cell populations are specifically related to changes resulting from expression of the retrovirally encoded TCR subunit, and not a result of the random outgrowth of clonal populations of T cells.
The ovASBN retroviral vector directs sustained TCR expression in the absence of drug selection
The results from Figure 3 imply that the inability of B6 ovASBN-vector cells to function in a therapeutic manner was most likely a direct consequence of the failure of these cells to maintain retrovirally encoded Vb5 expression in vivo. This was unexpected, as we had previously shown in vitro that B6 ovASBN-vector cells both express the retrovirally encoded Vb5 and function in an antigen-specific manner dependent on this Vb5 expression. To help clarify this in vitro and in vivo discrepancy, we evaluated whether retrovirally mediated Vb5 expression could be maintained in vitro for a long period of time without drug selection. We used 58a À b À cells, an immortalized hybridoma T-cell line defective in the cell surface expression of the endogenousTCR a-and b-subunits. 29 After transduction with the ovASBN retroviral vector and selecting for drug resistance, we split the 58a À b À cultures into two separate cultures with or without G418 drug selection. In both conditions, the 58a À b À cells maintained equivalent levels of CD3e on their surface (Figure 4) , indicating the cells maintained simultaneous surface expression of both the a and b TCR gene products. Loss of cell surface expression of either retrovirally encoded TCR subunit would have been indicated by a loss of CD3e surface staining, given that 58a À b À cells lack endogenous a and b TCR gene products, both of which are required to maintain CD3e surface expression. 21, 29 Thus, these results show that even without drug selection, simultaneous expression of the two critical retrovirally encoded TCR gene products could be sustained for a long period of time in immortalized cells in vitro.
Generation of single-chain TCR retroviral constructs
As we did not find evidence explaining the loss of retrovirally mediated Vb5 expression using the immortalized 58a
À b À cells, we next evaluated this question in the more complex environment of the mature primary T cell. In this environment, the discrepancy between our in vitro and in vivo results could be a result of immunologic or technical reasons. For example, there might be a specific deficiency in vivo in the ability of the exogenous TCR b gene product to associate with the appropriate protein subunits necessary for localization to the cell surface. Alternatively, the retroviral construct used in our experiments may not direct the expression of all exogenous genes equally in vivo, and specifically, there might be a defect in the expression of the OT-I TCR b gene in the ovASBN retroviral vector. This corresponds to the SRa promoter gene position of the 'pg1 SAMEN SRa' vector.
To gain a better understanding of which of these two possibilities might be affecting our model, we designed eight new single TCR subunit retroviral constructs using either the Vb5 or the Va2 TCR subunit genes derived from the OT-I TCR (see Supplementary Figure 3a) . In six of these constructs, the inserted TCR subunit gene was positioned to be under the transcriptional control of the MoMLV LTR promoter. These LTR-driven single-chain constructs included both Vb5 single-chain constructs (ovBN, ovBSN and ovBH) and Va2 single-chain constructs (ovAN, ovASN and ovAH). We also generated two single-chain retroviral constructs where the SRa promoter drove the expression of either the Vb5 (ovSBN) or the Va2 (ovSAN) gene. In six of the eight of these constructs, we included a drug resistance gene neomycin (ovAN, ovASN,  ovSAN, ovBN, ovBSN and ovSBN) and in two of the eight constructs we used the hygromycin resistance gene (ovAH and ovBH). In all cases, expression of the drug resistance gene was driven off an IRES from the encephalomyocarditis virus. For all constructs, retroviral transduction of target cells resulted in the acquisition of drug resistance corresponding to the relevant drug resistance gene (data not shown). To verify that each construct was also capable of directing cell surface expression of the relevant TCR subunit, we used a two-step transduction protocol of the 58a À b À cells. First, the 58a À b À cells were transduced with one of the two hygromycin-containing constructs (ovAH or ovBH) and selected in hygromycincontaining media to obtain a pure population of genetically modified cells. Second, the hygromycin-resistant cells (either the 58a were transduced with a neomycin-containing construct. These cells were then selected in G418-containing media to obtain a pure population of 58a À b À cells transduced with both a hygromycin and neomycin-containing construct. In all cases where 58a À b À cells were transduced with both Va2-and Vb5-containing retroviral vectors, a significant percentage of cells expressed CD3e (Supplementary Figure 3b and c) . As this CD3e surface expression is dependent on the simultaneous expression of both the a and b TCR subunits (as described for Figure 4 ), these results show that all eight constructs are capable of directing cell surface expression of their encoded TCR subunits.
Single-chain TCR retroviral constructs direct promoterspecific expression in vitro and in vivo Having established that our single-chain TCR retroviral constructs were capable of directing expression of the retrovirally encoded TCR subunit in 58a
À b À cells, we could now evaluate whether the failure to maintain ovASBN vector-encoded Vb5 expression in vivo was related to immunological issues associated with the ability of the exogenous TCR b chain to localize to the surface or technical issues linked to our retroviral construct. We assessed these two possibilities by retrovirally transducing primary T cells from C57BL/6 mice with one of the four retroviral constructs, namely ovASN, ovSAN ovBSN, and ovSBN. Drug-resistant primary T cells were designated B6 ovASN-vector , B6
ovSAN-vector , B6 ovBSN-vector , and B6 ovSBN-vector , respectively. These retrovirally transduced cell populations allowed us to compare, either in vitro or in vivo, the expression of different exogenous genes under the control of either the LTR or SRa promoter.
Expression of the retrovirally encoded Va2 and Vb5 TCR genes was first assessed in vitro. All four T-cell populations, B6 ovASN-vector , B6 ovSAN-vector , B6 ovBSN-vector , and B6 ovSBN-vector , directed expression of their specific retrovirally encoded TCR subunit gene when compared with control B6 control-vector T cells (Figure 5a ). Furthermore, as expected, only B6 ovASBN-vector T cells showed the expression of both retrovirally encoded Vb5 and Va2 TCR genes, again indicating that the changes in TCR expression were construct-specific.
We next evaluated the ability of B6 ovASN-vector and B6 ovSAN-vector T cells to maintain the expression of their retrovirally encoded Va2 gene in vivo after adoptive transfer into mice. As a prerequisite, we show that 2 weeks after adoptive transfer, both B6 ovASN-vector and B6 ovSAN-vector T cells persist in the spleen (Figure 5b ). Furthermore, in Figures 5b and c, (Figures 6a and b) . Interestingly, extension of the culture conditions for just 2.5 weeks resulted in the selective loss of retrovirally encoded SRa-driven Va2 expression (B6 ovSAN-vector ) but not LTR-driven Va2 expression (B6 ovASBN-vector , B6 ovASN-vector ). We observed a similar reduction in retrovirally encoded SRa-driven Vb5 expression over time when comparing the SRa-driven B6 ovASBN-vector and B6 ovSBN-vector T cells with LTR-driven B6 ovBSN-vector T cells (Figure 6c ). Although the loss in SRa-driven gene expression in vitro was not as dramatic as we observed in vivo after adoptive transfer of T cells into mice (Figures 3 and 5c ), these in vitro results demonstrate the external factors leading to the loss of SRa-driven gene expression are not exclusively present in vivo.
Adoptively transferred retrovirally modified T cells transition into memory T cells, persist in a nonlymphopenic environment, and maintain retrovirally encoded transgene expression Successful therapy by adoptive transfer of retrovirally modified T cells will in many circumstances require the ability of the adoptively transferred cells to persist and exhibit sustained gene expression. We evaluated this in our model using nonlymphopenic C57BL/6 mice as recipients. Nine months after the adoptive transfer of 10 million B6 ovASBN-vector cells T cells, we observed the persistence of these cells in multiple organs including the spleen, LN and PBL (Figures 7a and b) . Within the lymphocyte gate based on forward scatter and side scatter properties, these donor T cells represented roughly 0.5-1% of the total cells. As a percentage of total CD8 þ T cells, the persistence of adoptively transferred cells was even more impressive, as roughly 3-5% of the total CD8 þ cells were of donor origin (data not shown). Expression of Va2 and Vb5 was compared in donor and host T cells (Figure 7a) . As was observed immediately after adoptive transfer, we did not detect a level of Vb5 expression on donor B6
ovASBN-vector cells that differed from that of host T cells. However, donor B6 ovASBN-vector cells did maintain high but heterogeneous level of Va2 when compared with host T cells. These results clearly demonstrate that not only did adoptively transferred B6 ovASBN-vector cells persist in an unirradiated host but also they maintained expression of the Va2 transgene at a level comparable to that seen immediately after transfer.
To further assess these adoptively transferred T cells, we assessed them for the expression of markers of memory T cells. Nine months after transfer, these cells expressed high levels of CD44 and CD62L, markers consistent with central memory phenotype 10, 30 ( Figure 7c ). Consistent with this phenotype, these cells also lacked expression of CD25 and CD69 (data not shown).
Discussion
One of the most significant hurdles to achieving therapeutically successful gene therapy for a broader range of human diseases and genetic disorders is attaining sustained multigene expression from a single construct in vivo. Generic issues relevant to this include (1) the persistence and trafficking of the transduced cells in vivo, (2) the successful vector-driven expression of the target gene and (3) the subsequent duration of gene expression. To contribute to a better understanding of the issues relevant to attaining such sustained gene expression, we evaluated retrovirally mediated gene expression on adoptively transferred murine T cells in the context of antigen-specific TCR transduction. Specifically, we began these studies by using a retroviral vector encoding the expression of three distinct genes, and we showed, using an immortalized cell line, that, in vitro, we could achieve sustained and simultaneous gene expression of all three vector genes independent of drug selection. However, contrary to our initial prediction, this pattern of gene expression was not present in vivo, and following the adoptive transfer of retrovirally modified primary T cells, there was a dramatic and selective loss in expression of one of the three vector genes. This loss of gene expression in vivo was associated with the placement of the transgene in a promoter-specific vector position, as when we generated alternative promoter-specific retroviral vectors, we were able to reproduce the promoter-specific and transgene positional selective loss of gene expression in vivo. Upon careful examination, we also observed a more subtle and gradual loss of gene expression in extended in vitro cultures of primary retrovirally modified T cells. Interestingly, this was not observed in experiments using the artificial 58a À b À cell line, indicating a difference between primary T cell cultures and immortalized T cell lines. Importantly, despite this discordance in gene expression in specific situations, we found that retrovirally modified T cells could persist in a nonlymphopenic mouse for over 9 months and that these adoptively transferred T cells exhibited a phenotype consistent with Discordant TCR gene expression in vivo MP Rubinstein et al memory T cells. Furthermore, these retrovirally modified T cells were able to maintain the expression of a retrovirally encoded gene for more than 9 months in vivo despite a lack of drug selection. A wide variety of mechanisms have been reported that may lead to the loss of promoter-specific gene expression in vivo. 12, [31] [32] [33] [34] [35] [36] [37] In many studies, DNA methylation has been linked to the loss of transgene expression; however, it is unclear whether such methylation plays a causative role or is a secondary consequence of other mechanisms. 32 Perhaps, more clinically relevant than completely understanding these molecular details are determining the external factors that may modify retrovirally mediated gene expression. In the context of T cells, one particularly relevant report showed that the activation state of T cells may affect their ability to direct gene expression. Specifically, Quinn et al. 38 showed that they could rescue LTR promoter-driven transgene expression in T cells by stimulation and activation through the TCR. However, this activation state-dependent re-induction of gene expression did not appear to be relevant in our studies, as we were unable to rescue SRa promoter-driven transgene expression by re-stimulation (with anti-CD3e/ CD28) of retrovirally modified T cells either in vitro or ex vivo (data not shown).
Two alternative explanations for the apparent loss of gene expression we observed in vivo might be (1) the selective rejection of the donor T cells as a result of transgene expression 39, 40 or (2) toxicity associated with transgene expression. We think that these possibilities are not likely, as the relevant transgene could be expressed at high levels in vivo when linked with the LTR promoter instead of the SRa promoter. Numerous other mechanisms that could play a contributory role to our observed loss of gene expression have also been reported. For example, expression of the neomycin resistance gene has been linked to problems with gene expression. [41] [42] [43] Although we cannot directly exclude any of these mechanisms as contributory, our results suggest either (1) a problem directly associated with the SRa promoter's ability to maintain gene expression in vivo on murine T cells or (2) a problem indirectly related to the SRa promoter gene position in the specific retroviral construct used in these studies. Thus, our results would dictate the use of caution in the evaluation or application of either SRa promoter containing vectors or pgSAMEN-related retroviral vectors. To our knowledge, there is no evidence that the SRa promoter can drive transgene expression directly in peripheral T cells in vivo, although, as with our studies, it has been reported that the SRa promoter can drive transgene expression in T cells in vitro. 44, 45 Interestingly, there is also conflicting data as to whether SRadriven transgene expression occurs in the thymus. 46, 47 Further studies will be needed to elucidate the causative agent for our observed loss of gene expression.
Perhaps the most important observation from our study was the inability of in vitro assays to adequately predict levels of multigene retroviral construct expression in vivo. In particular, the linked expression of two genes in vitro was not indicative of linked expression in vivo. While this discordance was most apparent from the in vitro evaluation of the retrovirally transduced immortalized cell line, we also observed this phenomenon, although to a lesser degree, when retrovirally transduced primary T cells were used for evaluation in vitro. These results are of particular concern, as in vitro assays are often used to predict results in vivo. [48] [49] [50] [51] [52] [53] [54] [55] Moreover, immortalized cell lines, which exhibited properties of greatest discordance to in vivo results, are normally of greatest ease to work with and thus often the most attractive candidates to evaluate the ability of retroviral vectors to direct gene expression. Our results suggest that careful consideration be given to the different physiological conditions present in vitro and in vivo.
The capacity of T cells in our model to survive in vivo is noteworthy. In most studies showing the persistence of genetically modified T lymphocytes, the recipients were lymphopenic. 6, 8, 54, [56] [57] [58] In such settings, donor T cells face reduced competition with host lymphocytes and persist much more effectively. 11 In our study, however, recipients were not lymphopenic, and thus, the ability to detect a significant percentage of donor T cells expressing one of the retrovirally encoded transgenes at 9 months is particularly impressive.
It is unclear why T cells generated through our T-cell transduction protocol persisted so effectively, but several factors may be relevant. Primarily, T cells were cultured for prolonged periods of time prior to injection using a sequential activation and expansion strategy. 24, 25 Furthermore, our retroviral transduction protocol involved the stimulation of T cells from bulk splenocyte cultures with supernatant harvested from third-party cells. These culture conditions may be permissive for the presence of factors with potent T-cell co-stimulatory properties. [59] [60] [61] [62] [63] If these activation and culture conditions are indeed critical to preconditioning T cells for the long-term survival following adoptive transfer, it may indicate the need for careful consideration of attempts to genetically modify T cells with newer viral vectors that do not require cell division 64 and may inadvertently not provide crucial co-stimulatory factors.
Conclusion
Developing the technology to modify cells genetically and to direct complex multigene expression for sustained periods of time in vivo will be the cornerstone for improved therapies to a growing list of human disorders. Our study exemplifies the complexity of technically relevant issues that must be understood to achieve appropriate multigene expression. In particular, interpretation of our results dictates the use of caution in using in vitro assays or alternative cell types as a surrogate for predicting retrovirally mediated expression in vivo. However, rather than being pessimistic, we believe our results are a cause for optimism, as we demonstrated that retrovirally modified T cells not only were capable of persisting but also were directing sustained gene expression in these cells. To date, retroviral vectors have been used with varying degrees of success in gene therapy trials in which the therapeutic effect was dependent on only one gene being expressed. Our study provides insight into the technically demanding issues that will be relevant to designing appropriate retroviral vectors for successful multigene therapy.
